Behçet's Disease Clinical Trial
Verified date | October 2012 |
Source | Turkish Ophthalmology Society |
Contact | n/a |
Is FDA regulated | No |
Health authority | Turkey: Ethics Committee |
Study type | Observational |
Objectives: Behçet's disease (BD) is a systemic vasculitis. Since vascular endothelial
dysfunction plays a prominent role in the pathogenesis of the disease, we considered
angiogenic cytokines as an interesting target for investigation in BD. The aim of this study
was to investigate the possible role of angiogenin, vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) in the pathogenesis of BD.
Design and Methods: Sixty five patients with BD and 21 healthy control subjects were
included in the study. Serum angiogenin, bFGF and VEGF concentrations were determined by
using in vitro enzyme immunoassay (ELISA) kits according to the manufacturer's instructions.
Status | Completed |
Enrollment | 86 |
Est. completion date | February 2012 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - age between 18-65 - fulfilling the international diagnostic criteria for Behçet's disease Exclusion Criteria: - to have another systemic disease |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Turkey | Ankara University, Faculty of Medicine, Department of Ophthalmology | Ankara |
Lead Sponsor | Collaborator |
---|---|
Turkish Ophthalmology Society |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Serum levels of VEGF in Behçet's patients with or without ocular involvement | 1 year | No | |
Primary | Serum levels of angiogenin in Behçet's patients with or without ocular involvement | The median serum angiogenin level was significantly higher in all patients with BD than controls (P=0.001). However there was no statistically significant difference between all patients and patients with or without ocular involvement. The mean serum bFGF and the median serum VEGF levels were higher in patients with ocular involvement than all patients, patients without ocular involvement and controls. But these differences did not reach statistical significance. | 1 year | Yes |
Secondary | Serum levels of bFGF in Behçet's patients with or without ocular involvement | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06145893 -
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
|
Phase 3 | |
Recruiting |
NCT05767047 -
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
|
Phase 3 | |
Not yet recruiting |
NCT06296004 -
Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease
|
||
Completed |
NCT02620618 -
Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study
|
Phase 1/Phase 2 | |
Completed |
NCT01780363 -
MEVALONATE KINASE GENE MUTATIONS AND THEIR CLINICAL CORRELATIONS IN BEHÇET'S DISEASE
|
N/A | |
Completed |
NCT01584778 -
Behçet's Disease and Eosinophil Cationic Protein
|
N/A |